Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

756 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy for Multiple Myeloma.
Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Tamura H, et al. Among authors: inokuchi k. Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009. Cancers (Basel). 2019. PMID: 31842518 Free PMC article. Review.
Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Isono N, et al. Among authors: inokuchi k. Leuk Lymphoma. 2016 Sep;57(9):2204-7. doi: 10.3109/10428194.2015.1126589. Epub 2015 Dec 24. Leuk Lymphoma. 2016. PMID: 26699798 Clinical Trial. No abstract available.
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, Moriya K, Choi I, Tamada K, Inokuchi K. Ishibashi M, et al. Among authors: inokuchi k. Cancer Immunol Res. 2016 Sep 2;4(9):779-88. doi: 10.1158/2326-6066.CIR-15-0296. Epub 2016 Jul 20. Cancer Immunol Res. 2016. PMID: 27440711
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: inokuchi k. Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410677 Free PMC article.
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: inokuchi k. Mol Cancer Res. 2020 Apr;18(4):632-643. doi: 10.1158/1541-7786.MCR-19-0391. Epub 2020 Jan 23. Mol Cancer Res. 2020. PMID: 31974290
756 results